When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old patient whose sickle cell disease left them with ...

For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...

UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease. The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 ...

For generations, Sickle Cell Disease has been a devastating illness affecting millions of people around the world, ...

This story is free to read because readers choose to support LAist. If you find value in independent local reporting, make a donation to power our newsroom today. For more than a year, Victoria Gray's ...

For years, researchers have been trying to figure out how to treat inherited blood disorders like sickle cell disease without causing new health problems in the process. Now, a team of scientists from ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending a CRISPR gene editing-based treatment for severe sickle cell disease (SCD). The regulator said ...

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Editas Medicine said Tuesday it will ...

Victoria Gray, the first person cured of sickle cell using CRISPR gene editing therapies, spoke in Fargo about her journey and the need to lower the $2M treatment cost. Victoria Gray, cured of sickle ...

In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, marking an exciting new chapter in the treatment of ...